Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 5:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Aciphex Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare Bioavailability of AZD5055 Film-coated Tablet With AZD5055 Oral Suspension and to Assess the Effect of Food and an Acid Reducing Agent on Pharmacokinetics (PK) of AZD5055 in Healthy Subjects.

NCT05630677
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AZD5055 solution for infusion, AZD5055 oral suspension, AZD5055 film-coated tablet, Rabeprazole, Delayed-release tablet
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2024 · Synced Sep 6, 2026, 5:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Study of Rabeprazole Sodium Delayed-Release Tablets 20 mg to Aciphex® Tablets 20 mg

NCT00649194
View directory record Official record
Conditions
Healthy
Interventions
Rabeprazole Sodium Delayed-Release Tablets 20 mg, Aciphex® Tablets 20 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 6, 2026, 5:51 AM EDT
Completed Phase 2Phase 3 Interventional

Laryngopharyngeal Reflux and Proton Pump Inhibitor (PPI) Treatment

NCT00204698
View directory record Official record
Conditions
Laryngopharyngeal Reflux
Interventions
Aciphex
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 15, 2008 · Synced Sep 6, 2026, 5:51 AM EDT
Completed Phase 3 Interventional Results available

Comparing the Efficacy, Safety, and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD)

NCT00911534
View directory record Official record
Conditions
Symptomatic Gastroesophageal Reflux Disease (sGERD)
Interventions
rabeprazole sodium, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
98
States / cities
Athens, Alabama • Huntsville, Alabama • Tucson, Arizona + 87 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2016 · Synced Sep 6, 2026, 5:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Acalabrutinib Suspension to Evaluate Relative Bioavailability and Proton-pump Inhibitor Effect in Healthy Volunteers

NCT04435483
View directory record Official record
Conditions
Pharmacokinetics, Bioavailability
Interventions
Acalabrutinib Treatment A, Acalabrutinib Treatment B, Acalabrutinib Treatment C
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Sep 6, 2026, 5:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic and Relative Bioavailability Study With Rabeprazole Sodium in Healthy Adult Volunteers

NCT01101646
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
rabeprazole sodium
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 27, 2014 · Synced Sep 6, 2026, 5:51 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Rabeprazole in Infants With Gastroesophageal Erosive Reflux Disease (GERD)

NCT00992589
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Rabeprazole sodium 5 mg, Rabeprazole sodium 10 mg, Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
1 Month to 11 Months
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
43
States / cities
Birmingham, Alabama • Columbiana, Alabama • Dothan, Alabama + 40 more
Source: ClinicalTrials.gov public record
Updated May 21, 2013 · Synced Sep 6, 2026, 5:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Proton Pump Inhibitor (PPI, Rabeprazole) Effect On Tablet Formulation Of Palbociclib

NCT03220191
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Palbociclib, Rabeprazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 9, 2017 · Synced Sep 6, 2026, 5:51 AM EDT
Completed Phase 1 Interventional

A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis

NCT02655614
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
GDC-0134, Placebo, Rabeprazole, Midazolam, Caffeine
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
8
States / cities
San Francisco, California • Jacksonville, Florida • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Sep 6, 2026, 5:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study To Investigate The Potential Effect Of Proton Pump Inhibitor On The Pharmacokinetics Of Palbociclib (PD-0332991)

NCT01918176
View directory record Official record
Conditions
Healthy
Interventions
Palbociclib alone, Palbociclib + Rabeprazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 7, 2015 · Synced Sep 6, 2026, 5:51 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of RO7890597 in Healthy Adult Volunteers

NCT07797478
View directory record Official record
Conditions
Healthy Volunteers
Interventions
RO7890597, Placebo, Rabeprazole, Itraconazole
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
139 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 6, 2026, 5:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pilot Study To Investigate The Effect Of Concurrent Antacid Administration On The Bioavailability Of Six Experimental Formulations Of Palbociclib

NCT02311946
View directory record Official record
Conditions
Healthy
Interventions
Palbociclib Alone, Palbociclib + Rabeprazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
3
States / cities
Miami, Florida • South Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Sep 6, 2026, 5:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy Participants

NCT05330858
View directory record Official record
Conditions
Pharmacokinetics
Interventions
ESK-001, Rabeprazole
Drug
Lead sponsor
Alumis Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Sep 6, 2026, 5:51 AM EDT
Completed Phase 2 Interventional Results available

A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD)

NCT02637557
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
IW-3718, Matching Placebo, PPI
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
62
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Sep 6, 2026, 5:51 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Role of Pain Modulation in GERD Patients Who Failed Standard Dose PPI

NCT00539240
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Rabeprazole 20mg, placebo dinner and bedtime, Rabeprazole 20 mg two times, Placebo at bedtime, Rabeprazole 20mg,placebo dinner ,Low dose Tricyclic Antidepressant
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 80 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 17, 2014 · Synced Sep 6, 2026, 5:51 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Different Forms of the Study Medicine Called PF-08049820 Are Absorbed and Eliminated in Healthy Adults

NCT07597928
View directory record Official record
Conditions
Healthy Adults, Healthy
Interventions
PF-08049820, Rabeprazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 6, 2026, 5:51 AM EDT
Completed Phase 1 Interventional

A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors

NCT01954043
View directory record Official record
Conditions
Cancer
Interventions
Dabrafenib 150 mg twice a day (BID), Rabeprazole 40 mg once daily (OD), Rifampin 600 mg OD
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Goodyear, Arizona • Dallas, Texas • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Sep 6, 2026, 5:51 AM EDT
Completed Phase 1 Interventional

A Study of Single and Multiple Doses of Rabeprazole in Pediatric Patients With Gastroesophageal Reflux Disease (GERD) 1 to 11 Months Old, Inclusive

NCT00747526
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Rabeprazole sodium 5 mg, Rabeprazole sodium 10 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
1 Month to 11 Months
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
13
States / cities
Little Rock, Arkansas • Oakland, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2013 · Synced Sep 6, 2026, 5:51 AM EDT
Completed Phase 3 Interventional

Evaluate the Effects on Asthma Control of Rabeprazole Given Twice Daily in Subjects With Asthma.

NCT00214552
View directory record Official record
Conditions
Asthma, Gastroesophageal Reflux Disease
Interventions
rabeprazole
Drug
Lead sponsor
Associated Scientists to Help Minimize Allergies
Other
Eligibility
18 Years to 85 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
2
States / cities
Richland, Washington • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 22, 2011 · Synced Sep 6, 2026, 5:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effects of Acid Reducing Agents on Pharmacokinetics of PC14586 in Healthy Participants

NCT06054464
View directory record Official record
Conditions
Healthy Volunteers
Interventions
PC14586, Rabeprazole, Famotidine
Drug
Lead sponsor
PMV Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Sep 6, 2026, 5:51 AM EDT
Completed Phase 4 Interventional

Comparison of the Nighttime Effects of Two Different Drugs on Subjects With GERD

NCT00304421
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
rabeprazole, pantoprazole
Drug
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2007 · Synced Sep 6, 2026, 5:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study of the Effect of Rabeprazole, Itraconazole or Fluconazole on the Pharmacokinetics of Vismodegib

NCT01772290
View directory record Official record
Conditions
Healthy Volunteer
Interventions
fluconazole, itraconazole, rabeprazole, vismodegib
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 6, 2026, 5:51 AM EDT
Completed Phase 4 Interventional

Role of Pain Modulation in GERD Patients Who Failed Standard Dose Proton Pump Inhibitors (PPI)

NCT00251732
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Standard dose (once daily) PPI plus low-dose antidepressant, Double dose PPI plus evening placebo, Rabeprazole , placebo, placebo
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 18, 2010 · Synced Sep 6, 2026, 5:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fed Study of Rabeprazole Sodium Tablets 20 mg and Aciphex® Tablets 20 mg

NCT00649493
View directory record Official record
Conditions
Healthy
Interventions
Rabeprazole Sodium Tablets 20 mg, Aciphex® Tablets 20 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
8 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Sep 6, 2026, 5:51 AM EDT